Cargando…
The Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease
Depression is a leading cause of disability globally, with a prevalence of 3.8% among the whole population, 5% of the adult population, and 5.7% of the elderly population over 60 years of age. There is evidence that depression is linked to certain neurodegenerative diseases, one being Alzheimer’s di...
Autores principales: | Mohammad Shehata, Islam, Masood, Waniyah, Nemr, Nouran, Anderson, Alexandra, Bhusal, Kamal, Edinoff, Amber N., Cornett, Elyse M., Kaye, Adam M., Kaye, Alan D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9036213/ https://www.ncbi.nlm.nih.gov/pubmed/35466206 http://dx.doi.org/10.3390/neurolint14020025 |
Ejemplares similares
-
Updated Perspectives on the Neurobiology of Substance Use Disorders Using Neuroimaging
por: Murnane, Kevin S, et al.
Publicado: (2023) -
Ketamine Evolving Clinical Roles and Potential Effects with Cognitive, Motor and Driving Ability
por: Edinoff, Amber N., et al.
Publicado: (2023) -
Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence
por: Edinoff, Amber N., et al.
Publicado: (2022) -
Pediatric obesity and anesthetic challenges of metabolic surgery
por: Hashim, Ahmed, et al.
Publicado: (2022) -
Bremelanotide for Treatment of Female Hypoactive Sexual Desire
por: Edinoff, Amber N., et al.
Publicado: (2022)